Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

3(38%)

Results Posted

0%(0 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_1

88%

Ph phase_2

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

7(87.5%)

Phase 2Efficacy & side effects

1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(2)

Terminated(2)

Detailed Status

Recruiting3

Completed2

Terminated2

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 17 (87.5%)

Phase 21 (12.5%)

Trials by Status

completed225%

recruiting338%

terminated225%

not_yet_recruiting113%

Recent Activity

3 active trials

Showing 5 of 8

completedphase_1

Clinical Trials (8)

Showing 8 of 8 trials

NCT04386967Phase 1

OH2 Injection in Solid Tumors

Completed

NCT05235074Phase 1

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

Completed

NCT05248789Phase 2

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Terminated

NCT04616443Phase 1

OH2 Injection in Combination With HX008 for Melanoma.

Recruiting

NCT05954091Phase 1

OH2 Administered by Intratumoral Injection

Not Yet Recruiting

NCT05698459Phase 1

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

Recruiting

NCT05232136Phase 1

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Recruiting

NCT04637698Phase 1

OH2 Oncolytic Viral Therapy in Pancreatic Cancer

Terminated

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8